Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
10 evidence topics · 6 sources
Androgen receptor signaling as the driver of castration resistance
“Over the past ten years, preclinical studies implicating sustained androgen receptor (AR) signaling as the primary driver of castration resistant prostate cancer (CRPC) led to the development of novel agents targeting the AR pathway that are now in widespread clinical use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this review, we highlight emerging mechanisms of acquired resistance to these contemporary therapies, which fall into the three broad categories of restored AR signaling, AR bypass signaling and complete AR independence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor pathway alterations in metastatic biopsies
“In aggregate 107/150 (71.3%) of cases harbored AR pathway aberrations, the majority of which were direct alterations affecting AR through amplification and mutation (Fig. 4A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The high frequency of AR pathway alterations in this cohort strongly implies that the vast majority of mCRPC affected individuals remain dependent on AR signaling for viability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary and acquired resistance to androgen receptor pathway inhibitors
“Although enzalutamide and abiraterone represent breakthroughs in the treatment of metastatic castration-resistant prostate cancer, approximately 20 to 40% of patients have no response to these agents with respect to prostate-specific antigen (PSA) levels (i.e., they have primary resistance).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who initially have a response to enzalutamide or abiraterone, virtually all eventually acquire secondary resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor splice variant 7 and cross-resistance to enzalutamide and abiraterone
“The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among men receiving enzalutamide, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 53%, P = 0.004)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, among men receiving abiraterone, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 68%, P = 0.004)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor bypass through the glucocorticoid receptor
“Recent work reveals a novel AR pathway resistance mechanism analogous to one originally described for kinase inhibitors, in which signaling downstream of the targeted kinase is restored by activation of a related kinase not targeted by the inhibitor” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lineage plasticity and neuroendocrine differentiation after androgen receptor pathway inhibitors
“With the growing clinical use of abiraterone and enzalutamide, it is increasingly appreciated that some men can relapse with clinically aggressive variants of PCa with reduced or absent AR expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, wherein tumor cells demonstrate low to absent AR expression and often neuroendocrine features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EZH2 expression in castration-resistant neuroendocrine prostate cancer
PRC2 and EZH2 inhibition restoring antiandrogen sensitivity in preclinical models
“Ezh2 is the enzymatic component of the Polycomb Repressive complex 2 that methylates the lysine 27 residue of histone H3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EZH2 as an androgen receptor coactivator in castration-resistant cells
“Here we report that the oncogenic function of EZH2 in castration-resistant prostate cancer (CRPC) is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a co-activator for critical transcription factors including the androgen receptor (AR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote